KEI Comments Regarding NIH Exclusive License to Lyell Immunopharma for Cell Therapy Cancer Treatment

On June 8, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) concerning the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” (86 FR 27852). The inventions to be… Continue Reading

KEI Comments Concerning NIH Exclusive License to Kantum Pharma

Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on June 8, 2021 regarding the “Prospective Grant of an Exclusive Patent License: P2Y14 Receptor Antagonists To Treat Kidney and Lung Inflammation” (86 FR 27858). The license… Continue Reading

KEI Comments to the NIH Regarding Prospective Exclusive License to UK firm Mevox

On June 2, 2021, Knowledge Ecology International (KEI) filed comments with the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development, Commercialization, and Use of Protein-Based Vaccines Expressing Recombinant Measles and Mumps Immunogens for… Continue Reading

KEI Comments on NIH Exclusive License to Australian firm SubRed

On Monday April 26, 2021, Knowledge Ecology International submitted comments regarding the “Prospective Grant of an Exclusive Patent License: N-butyldeoxynojirimycin To Treat Smith-Lemli Opitz Syndrome (SLOS) and Diseases That Exhibit a Similar NPC-Like Cellular Phenotype” (86 FR 18545) by the… Continue Reading

KEI Comments Regarding NIH Exclusive License to Memorial Sloan Kettering Cancer Center

(Update: The NIH provided a response to our comments on April 15, 2021.) Knowledge Ecology International (KEI) submitted comments on April 14, 2021 to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of Exclusive Patent… Continue Reading

KEI Comments on NIH Exclusive License to Norwegian Firm Zelluna

(Update: The NIH provided a response to our comments on April 15, 2021.) On Wednesday April 14, 2021, Knowledge Ecology International (KEI) filed comments with the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License:… Continue Reading

KEI Comments on NIH Exclusive License to Ridgeback for FDA-approved Ebola Treatment

(Update: On April 30, 2021, the NIH sent a response to KEI’s comments.) On March 30, 2021, Knowledge Ecology International (KEI) filed comments regarding the National Institute of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID), “Prospective Grant… Continue Reading

KEI Comments on NIH Proposed Exclusive License to Iovance for Cancer Cell Therapy

On Friday March 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy” (86 FR 11548). The technology is… Continue Reading

Comments on NIST Proposed Revisions to Bayh-Dole Act

(KEI has an email list to discuss this issue here: http://lists.keionline.org/mailman/listinfo/bayh-dole-regulations_lists.keionline.org) The Department of Commerce’s National Institute of Standards and Technology (NIST) published on January 4, 2021, a request for comments on changes in regulations related to the Bayh-Dole Act… Continue Reading

KEI Comments to NIH Proposed Exclusive License to Ziopharm for Cell Therapy Cancer Treatment

On February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer” to Ziopharm Oncology, Inc. (Ziopharm). The… Continue Reading